Skip to main content
SpringerLink
Log in
Book cover

Dementia with Lewy Bodies pp 157–170Cite as

123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies

  • Chapter
  • First Online:

  • 1306 Accesses

Abstract

Differential diagnosis of dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD) and other dementias is essential for better management. Metaiodobenzylguanidine (MIBG) is a physiological analogue of norepinephrine, and 123I-MIBG myocardial scintigraphy has been used as a noninvasive tool for estimating myocardial sympathetic nerve damage due to various disorders such as heart and neurologic diseases. Degeneration of the cardiac sympathetic nerves is a neuropathological feature of Lewy body diseases including Parkinson’s disease and DLB. Multiple single-center studies, including ours, reported very high sensitivity and specificity of 123I-MIBG myocardial scintigraphy for the differential diagnosis of DLB from AD and other dementias; further, our first multicenter study of DLB with the standardized technique [1] substantiated the high diagnostic accuracy of 123I-MIBG myocardial scintigraphy, which was comparable to that of 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) SPECT multicenter study [2]. In the current version of the consensus diagnostic criteria for DLB [3], 123I-FP-CIT SPECT was listed as one of the suggestive features of DLB, whereas 123I-MIBG myocardial scintigraphy was listed as one of the supportive features. As 123I-MIBG myocardial scintigraphy has been proved to have high diagnostic specificity, it is recommended to upgrade the abnormal MIBG myocardial scintigraphy to one of the suggestive features of DLB.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Yoshita M, Arai H, Arai T, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One. 2015;10:e0120540.

    Article  PubMed  PubMed Central  Google Scholar 

  2. McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.

    Article  PubMed  Google Scholar 

  3. McKeith I, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863–72.

    Article  CAS  PubMed  Google Scholar 

  4. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–24.

    Article  CAS  PubMed  Google Scholar 

  5. Lopez OL, Becker JT, Kaufer DI, et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol. 2002;59:43–6.

    Article  PubMed  Google Scholar 

  6. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050–8.

    Article  CAS  PubMed  Google Scholar 

  7. Ferman TJ, Boeve BF, Smith GE, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011;77:875–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.

    CAS  PubMed  Google Scholar 

  9. Dae MW, O’Connell JW, Botvinick EH, et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation. 1989;79:634–44.

    Article  CAS  PubMed  Google Scholar 

  10. Glowniak JV, Turner FE, Gray LL, et al. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med. 1989;30:1182–91.

    CAS  PubMed  Google Scholar 

  11. Nakajima K, Bunko H, Taki J, et al. Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 1990;119:1329–37.

    Article  CAS  PubMed  Google Scholar 

  12. Hakusui S, Yasuda T, Yanagi T, et al. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1994;49:81–4.

    Article  CAS  PubMed  Google Scholar 

  13. Iwasa K, Nakajima K, Yoshikawa H, et al. Decreased myocardial 123I-MIBG uptake in Parkinson’s disease. Acta Neurol Scand. 1998;97:303–6.

    Article  CAS  PubMed  Google Scholar 

  14. Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998;155:60–7.

    Article  CAS  PubMed  Google Scholar 

  15. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol. 1997;38 Suppl 2:2–7.

    PubMed  Google Scholar 

  16. Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology. 1999;52:1269–71.

    Article  CAS  PubMed  Google Scholar 

  17. Orimo S, Ozawa E, Oka T, et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology. 2001;57:1140–1.

    Article  CAS  PubMed  Google Scholar 

  18. Orimo S, Oka T, Miura H, et al. Sympathetic cardiac denervation in Parkinson’s disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;73:776–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mitsui J, Saito Y, Momose T, et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci. 2006;243:101–4.

    Article  CAS  PubMed  Google Scholar 

  20. Orimo S, Uchihara T, Nakamura A, et al. Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain. 2008;131:642–50.

    Article  PubMed  Google Scholar 

  21. Orimo S, Nakamura A, Uchihara T, et al. Relationship among degeneration of the cardiac sympathetic nerve, clinical features and neuropathological findings in dementia with Lewy bodies. Neuropathology. 2012;32 Suppl:62.

    Google Scholar 

  22. Mori H, Oda M, Komori T, et al. Lewy bodies in progressive supranuclear palsy. Acta Neuropathol. 2002;104:273–8.

    CAS  PubMed  Google Scholar 

  23. Orimo S, Kanazawa T, Nakamura A, et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol. 2007;113:81–6.

    Article  PubMed  Google Scholar 

  24. Nakajima K, Yoshita M, Matsuo S, et al. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging. 2008;52:378–87.

    CAS  PubMed  Google Scholar 

  25. Okuda K, Nakajima K, Hosoya T, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18:82–9.

    Article  PubMed  Google Scholar 

  26. Nakajima K, Okuda K, Matsuo S, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2012;39:113–19.

    Article  CAS  PubMed  Google Scholar 

  27. Nakajima K, Okuda K, Yoshimura M, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21:970–8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Hirayama M, Hakusui S, Koike Y, et al. A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1995;53:230–4.

    Article  CAS  PubMed  Google Scholar 

  29. Yoshida M, Fukumoto Y, Kuroda Y, et al. Sympathetic denervation of myocardium demonstrated by 123I-MIBG scintigraphy in pure progressive autonomic failure. Eur Neurol. 1997;38:291–6.

    Article  CAS  PubMed  Google Scholar 

  30. Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson’s disease. Nucl Med Commun. 1998;19:137–42.

    Article  CAS  PubMed  Google Scholar 

  31. Orimo S, Ozawa E, Nakade S, et al. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67:189–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Goldstein DS, Holmes C, Li ST, et al. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med. 2000;133:338–47.

    Article  CAS  PubMed  Google Scholar 

  33. Yoshita M. Value of MIBG in the differential diagnosis of neurodegenerative disorders. In: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Leenders KL, editors. PET and SPECT in neurology. New York/Berlin/Heidelberg: Springer; 2014. p. 437–49.

    Google Scholar 

  34. Miyamoto T, Miyamoto M, Inoue Y, et al. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology. 2006;67:2236–8.

    Article  CAS  PubMed  Google Scholar 

  35. Solanki KK, Bomanji J, Moyes J, et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13:513–21.

    Article  CAS  PubMed  Google Scholar 

  36. Yoshita M, Taki J, Yamada M. A clinical role for [123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001;71:583–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Watanabe H, Ieda T, Katayama T, et al. Cardiac 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2001;70:781–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Oide T, Tokuda T, Momose M, et al. Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer’s disease and dementia with Lewy bodies. Intern Med. 2003;42:686–90.

    Article  PubMed  Google Scholar 

  39. Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006;66:1850–4.

    Article  CAS  PubMed  Google Scholar 

  40. Hanyu H, Shimizu S, Hirao K, et al. The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord. 2006;22:379–84.

    Article  PubMed  Google Scholar 

  41. Hanyu H, Shimizu S, Hirao K, et al. Comparative value of brain perfusion SPECT and [123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2006;33:248–53.

    Article  PubMed  Google Scholar 

  42. Wada-Isoe K, Kitayama M, Nakaso K, et al. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci. 2007;260:33–7.

    Article  PubMed  Google Scholar 

  43. Inui Y, Toyama H, Manabe Y, et al. Evaluation of probable or possible dementia with lewy bodies using 123I-IMP brain perfusion SPECT, 123I-MIBG, and 99mTc-MIBI myocardial SPECT. J Nucl Med. 2007;48:1641–50.

    Article  PubMed  Google Scholar 

  44. Estorch M, Camacho V, Paredes P, et al. Cardiac 123I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging. 2008;35:1636–41.

    Article  PubMed  Google Scholar 

  45. Novellino F, Bagnato A, Salsone M, et al. Myocardial 123I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. Neurobiol Aging. 2010;31:1903–11.

    Article  PubMed  Google Scholar 

  46. Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging. 2012;22:111–17.

    Article  PubMed  Google Scholar 

  47. Schmidt SL, Correa PL, Tolentino JC, et al. Value of combining activated brain FDG-PET and cardiac MIBG for the differential diagnosis of dementia: differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult. Clin Nucl Med. 2008;33:398–401.

    Article  PubMed  Google Scholar 

  48. Sakamoto F, Shiraishi S, Yoshida M, et al. Diagnosis of dementia with Lewy bodies: diagnostic performance of combined 123I-IMP brain perfusion SPECT and 123I-MIBG myocardial scintigraphy. Ann Nucl Med. 2014;28:203–11.

    Article  PubMed  Google Scholar 

  49. Camacho V, Marquié M, Lleó A, et al. Cardiac sympathetic impairment parallels nigrostriatal degeneration in probable dementia with Lewy bodies. Q J Nucl Med Mol Imaging. 2011;55:476–83.

    CAS  PubMed  Google Scholar 

  50. Treglia G, Cason E, Cortelli P, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques? J Neuroimaging. 2014;24:149–54.

    Article  PubMed  Google Scholar 

  51. Noguchi-Shinohara M, Tokuda T, Yoshita M, et al. CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer’s disease. Brain Res. 2009;28:1–6.

    Article  Google Scholar 

  52. Fujishiro H, Nakamura S, Kitazawa M, et al. Early detection of dementia with Lewy bodies in patients with amnestic mild cognitive impairment using 123I-MIBG cardiac scintigraphy. J Neurol Sci. 2012;315:115–19.

    Article  PubMed  Google Scholar 

  53. Oda H, Ishii K, Terashima A, et al. Myocardial scintigraphy may predict the conversion to probable dementia with Lewy bodies. Neurology. 2013;81:1741–5.

    Article  PubMed  Google Scholar 

  54. Chui HC, Lyness SA, Sobel E, et al. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer’s disease. Arch Neurol. 1994;51:676–81.

    Article  CAS  PubMed  Google Scholar 

  55. Attems J, Quass M, Jellinger KA. Tau and α-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol. 2007;113:53–62.

    Article  CAS  PubMed  Google Scholar 

  56. White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis. 2009;18:713–25.

    PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported by the grant of Japan Foundation for Neuroscience and Mental Health (to M. Yamada). The funder had no role in preparation of the manuscript. The authors thank Ms. Etsuko Tsujiguchi for her secretarial assistance.

Author information

Authors and Affiliations

  1. Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, 920-8640, Japan

    Masahito Yamada, Mitsuhiro Yoshita, Miharu Samuraki & Junji Komatsu

  2. Department of Neurology, Hokuriku National Hospital, 5963 Nobusue, Nanto, Toyama, 939-1893, Japan

    Mitsuhiro Yoshita

  3. Department of Nuclear Medicine, Kanazawa University Hospital, 13-1, Takara-machi, Kanazawa, 920-8640, Japan

    Kenichi Nakajima

Authors
  1. Masahito Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuhiro Yoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miharu Samuraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junji Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenichi Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masahito Yamada .

Editor information

Editors and Affiliations

  1. Yokohama City University, Yokohama, Kanagawa, Japan

    Kenji Kosaka

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Japan KK

About this chapter

Cite this chapter

Yamada, M., Yoshita, M., Samuraki, M., Komatsu, J., Nakajima, K. (2017). 123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies. In: Kosaka, K. (eds) Dementia with Lewy Bodies. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55948-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55948-1_12

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55946-7

  • Online ISBN: 978-4-431-55948-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation